Efficacy of erythropoietin on dialysis in patients with beta thalassemia minor

Blood Purification

Volumn 22, Issue 5, 2004, Pages 453-460

  Di Iorio, Biagio ^a   De Nicola, Luca ^b   Bellizzi, Vincenzo ^a   Minutolo, Roberto ^b   Zamboli, Pasquale ^b   Rubino, Roberto ^c   Fuiano, Giorgio ^c   Conte, Giuseppe ^a,c  

^a Nephrology Unit   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c University of Catanzaro ^*  (Italy)

Author keywords

Blood transfusion; Erythropoietin; Hemodialysis; Thalassemia

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN;

ADULT; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSIS; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; ERYTHROCYTE; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE MASS; HEMOGLOBIN DETERMINATION; HUMAN; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

BETA-THALASSEMIA; BLOOD TRANSFUSION; ERYTHROPOIETIN; FEMALE; HEMATOLOGIC TESTS; HEMODYNAMIC PROCESSES; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 9244221698     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000080729     Document Type: Article

References (29)

1. Angastiniotis M, Modell B: Global epidemiology of hemoglobin disorders. Ann N Y Acad Sci 1998;850:251-269.
2. Rund D, Rachmilewitz E: New trends in the treatment of β-thalassemia. Crit Rev Oncol Hemat 2000;33:105-118.
3. Winearls CG, Hughes RT, Pippard MJ, Cotes PM: Erythropoietin dose requirement in a patient with HbH disease and renal failure. Nephrol Dial Transplant 1992;7:1052-1054.
4. Di Iorio BR, Aucella F, Stallone C, et al: The use of recombinant human erythropoietin in hemoglobinopathy and uremia. Dial Transplant 2001;30:368-372.
5. Lai KN, Wung KC, Li PK, Lui SF: Use of recombinant erythropoietin in thalassaemic patients on dialysis. Am J Kidney Dis 1992;19:239-245.
6. Cheng IKT, Lu HB, Wei DCC, et al: Influence of thalassemia on the response to erythropoietin in dialysis patients. Am J Nephrol 1993;13:142-148.
7. Cozma G, Cozma MC, Mattes U: Bene. cial effect of erythropoietin in β thalassemia patients on dialysis. Nephrol Dial Transplant 1992;7:82-83.
8. Prata MM, Teixeira JA, Teixeira de Sousa F, Martins C: Erythropoietin dose requirement in a patient with β-thalassemia and CRF. Nephrol Dial Transplant 1994;9:1211-1212.
9. Kagan A, Sinay-Triema L, Bar-Khayim Y: Erythropoietin for anemia of ESRD in β-thalassemia trait. Nephron 1992;62:229-230.
10. National Kidney Foundation: K/DOQI Clinical Practice Guidelines for Anemia in Chronic Kidney Disease 2000. Am J Kidney Dis 2001;37(suppl 1):S182-S238
11. European Best Practice Guidelines for the Management of Anaemia in Patients with CRF. Nephrol Dial Transplant 1999;14(suppl 5):S1-S50.
12. Di Iorio B, Guastaferro P, Gironda A, et al: La correzione dell'anemia nei pazienti in emodialisi con talassemia minor è possibile? G Ital Nefrol 2002;19:552-559.
13. De Montalembert M, Girot R, Mattlinger B, Lefrere JJ: Transfusion-dependent thalassemia: Viral complications (epidemiology and follow-up). Semin Hematol 1995;32:280-287.
14. Tarng DC, Huang TP, Chen TW, Yang WC: Erythropoietin hyporesponsiveness: From iron deficiency to iron overload. Kidney Int 1999;55(suppl 69):S107-S118.
15. Ifudu O, Feldman J, Friedman EA: The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. N Engl J Med 1996;15:420-425.
16. Bellizzi V, Minutolo R, Terracciano V, et al: Influence of the cyclic variation of hydration status on hemoglobin levels in hemodialysis patients. Am J Kidney Dis 2002;40:549-555.
17. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: The impact of anemia on cardiomyopathy, morbidity, and mortality in end-satge renal disease. Am J Kidney Dis 1996;28:53-61.
18. Di Iorio B, Aucella F, Stallone C, Bellizzi V: Talassemia minor: Indagine nazionale dei pazienti uremici in trattamento sostitutivo. G Ital Nefrol 2002;19:286-293.
19. Ansar MM, Kooloobandi A: Prevalence of hepatitis C virus infection in thalassemia and haemodialisis patients in north Iran-Rasht. J Viral Hepatitis 2002;9:390-392.
20. Yu ML, Chuang WL, Wang LY, et al: Status and natural course of GB virus C/hepatitis G virus infection among high-risk groups and volunteer blood donors in Taiwan. J Gastroen Hepatol 2000;15:1404-1410.
21. London GM: Left ventricular alterations and end-stage renal disease. Nephrol Dial Transplant 2002;17(suppl 1):S29-S36.
22. Chaignon M, Chen WT, Tarazi RC, et al: Effect of hemodialysis on blood volume distribution and cardiac output. Hypertension 1981;3:327-332.
23. Levin A, Thompson CR, Ethier J, et al: Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis 1999;34:125-134.
24. Hayashi T, Suzuki A, Shoji T, et al: Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 2000;35:250-256.
25. Collins AJ, Li S, Peter W, et al: Death hospitalization and economic associations among incident hemodialysis patients with hematocrit value of 36 to 39%. J Am Soc Nephrol 2001;12:2465-2473.
26. Pascual J, Teruel JL, Moya JL, Liano F, Jimenez-Mena M, Ortuno J: Regression of left ventricular hypertophy after partial correction of anemia with erythropoietin in patients on hemodialysis: A prospective study. Clin Nephrol 1991;38:174-176.
27. Martinez-Vea A, Bardaji A, Garcia C, Ridao C, Richart C, Oliver JA: Long-term myocardial effect of correction of anemia with recombinant human erythropoietin in aged patients on hemodialysis. Am J Kidney Dis 1992;19:353-357.
28. McMahon LP, Mason K, Skinner SL, et al: Effects of hemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant 2000;15:1425-1430.
29. Buur T, Lundberg M: Secondary effects of erythropoietin treatment on metabolism and dialysis efficacy in stable hemodialysis patients. Clin Nephrol 1990;34:230-235.